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The objective of the present prospective pharmacokinetic study was to describe the variability of plasma
gentamicin concentrations in critically ill patients with acute kidney injury (AKI) necessitating extended daily
diafiltration (EDD-f) using a population pharmacokinetic model and to subsequently perform Monte Carlo
dosing simulations to determine which dose regimen achieves the pharmacodynamic targets the most consis-
tently. We collected data from 28 gentamicin doses in 14 critically ill adult patients with AKI requiring EDD-f
and therapeutic gentamicin. Serial plasma samples were collected. A population pharmacokinetic model was
used to describe the pharmacokinetics of gentamicin and perform Monte Carlo simulations with doses of
between 3 mg/kg of body weight and 7 mg/kg and at various time points before commencement of EDD-f to
evaluate the optimal dosing regimen for achieving pharmacodynamic targets. A two-compartment pharmaco-
kinetic model adequately described the gentamicin clearance while patients were on and off EDD-f. The plasma
half-life of gentamicin during EDD-f was 13.8 h, whereas it was 153.4 h without EDD-f. Monte Carlo simula-
tions suggest that dosing with 6 mg/kg every 48 h either 30 min or 1 h before the commencement of EDD-f
results in 100% attainment of the target maximum concentration drug in plasma (<10 mg/liter) and sufficient
attainment of the target area under the concentration-time curve from 0 to 24 h (AUC0–24; 70 to 120
mg  h/liter). None of the simulated dosing regimens satisfactorily achieved the targets of the minimum
concentrations of drug in plasma (<1.0 mg/liter) at 24 h. In conclusion, dosing of gentamicin 30 min to 1 h
before the commencement of an EDD-f treatment enables attainment of target peak concentrations for
maximal therapeutic effect while enhancing drug clearance to minimize toxicity. Redosing in many patients
should occur after 48 h, and we recommend the use of therapeutic drug monitoring to guide dosing to optimize
achievement of the AUC0–24 targets.
Acute kidney injury (AKI) is an independent risk factor for
mortality in critically ill patients (5) and has a mortality rate as
high as 60% (20). Of all patients admitted to a critical care
unit, approximately 5% will develop AKI and at least 70% of
these patients will require renal replacement therapy (RRT)
(11). Extended daily diafiltration (EDD-f), also known as sus-
tained low-efficiency dialysis, is an emerging form of RRT
increasingly being used worldwide. EDD-f combines the con-
venience and efficiency of intermittent hemodialysis with the
stability of traditional continuous renal replacement therapy
into a 10- to 12-h treatment (16). This hybrid type of dialysis is
reported to have advantages over intermittent hemodialysis
and continuous RRT, including efficient solute removal with
minimum solute disequilibrium, improved hemodynamic sta-
bility, low anticoagulant needs, diminished cost, and improved
patient mobility (16). This has been confirmed with critically ill
patients (1). However, drug dosing remains a challenge to
critical care physicians, and to date few pharmacokinetic
studies of this specific dialysis modality have been under-
taken (7, 10).
In critically ill patients, a wide array of pathophysiological
changes which complicate antibiotic dosing can occur (17).
Changes in clearances and volumes of distribution for different
dialysis treatments have been widely described, although the
number and type of dialysis modalities and the consequent
altered capacity for drug clearance necessitate that pharmaco-
kinetic studies be undertaken to determine the precise dosing
requirements for a drug in the chosen dialysis modality (6).
Such information is vital in the context of antibiotic dosing,
particularly in patients with AKI, who have higher mortality
rates than other critically ill patients (5, 20).
Gentamicin is a widely used aminoglycoside antibiotic that
has an important role in treatment of infections in critical care
units. Gentamicin exhibits concentration-dependent bacterial
killing (13), requiring a maximum concentration in plasma
(Cmax) during a dosing period of at least 10 mg/liter (4). Fur-
ther to this, an area under the concentration-time curve from
0 to 24 h (AUC0–24) of 70 to 120 mg  h/liter has been reported
to be desirable for efficacy (4). Minimizing aminoglycoside
toxicity in patients receiving gentamicin is best achieved by
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minimizing the minimum concentration (Cmin) during a dosing
period. Emerging data support maintenance of an AUC0–24 of
120 mg  h/liter/day to minimize toxicity as well (4).
The aims of the present study were to describe the variability
of plasma gentamicin concentrations in critically ill patients
with AKI necessitating EDD-f using a population pharmaco-
kinetic model and to subsequently perform Monte Carlo dos-
ing simulations to determine a dose regimen that most consis-
tently achieves the pharmacodynamic targets.
MATERIALS AND METHODS
Patients. The present study was performed in a 13-bed intensive care unit of
a 530-bed hospital. Ethical approval to conduct the study was obtained from the
local institutional ethics committee (protocol 200620). Consent to participate
was obtained from the patient’s legally authorized representative.
Procedures. Critically ill adult patients with AKI requiring EDD-f and thera-
peutic gentamicin treatment were studied. In accordance with usual practice, all
patients had an indwelling arterial cannula. Patients were administered genta-
micin at the discretion of the treating physician.
Dialysis prescription. EDD-f was performed in all patients with a 4008S
hemodialysis machine (Fresenius Medical Care, Bad Homburg, Germany) using
Fresenius AV600S filters (surface area, 0.6 m2; Fresenius Medical Care). For
each patient, a central vein was cannulated with a standard dialysis vascular
catheter. A standardized prescription consisted of hemodiafiltration with a target
duration of 10 h (with 300 ml/min of blood and dialysate flow and 50 ml/min of
predilution). The target duration was rarely achieved, with EDD-f typically
occurring for a duration of 6 h. The biochemical composition of the dialysate and
bicarbonate-based replacement fluid was set according to the patient’s biochem-
istry. Data on the precise times for EDD-f commencement and cessation, due to
blood clotting on the filter or the end of treatment, were recorded.
Sample collection. Gentamicin was administered by a central venous line as a
30-min infusion. Samples of arterial blood were collected from an indwelling
arterial cannula before the drug administration (T0) and at 15 min (T15), T30,
T60, T120, T180, T300, T480, and T600 after the drug administration. Further
arterial blood samples were collected from each patient to establish the plasma
concentrations between EDD-f sessions. Sampling occurred during the first dos-
ing period and at subsequent dosing intervals where possible thereafter. EDD-f
was commenced at the discretion of the clinician and did not uniformly corre-
spond with the timing of gentamicin dosing.
Drug assay. Plasma gentamicin concentrations were determined using a Syn-
chron LX system assay (Beckman-Coulter Inc., Fullerton, CA). The within-run
coefficients of variation were estimated to be 7.1% at 2.2 mg/liter and 2.1% at 9.7
mg/liter. The lowest level of detection was 0.3 mg/liter.
Pharmacokinetic and statistical analysis. The concentration-versus-time data
for gentamicin in plasma were analyzed by a nonlinear mixed-effects modeling
approach (2) using NONMEM software (version 6.1; GloboMax LLC, Hanover,
MD) with double precision with a Compaq Visual Fortran compiler. Cmax and
Cmin were the observed values from the intensive sampling schedule. The
NONMEM runs were executed using Wings for NONMEM (WFN; version 6.1.3).
Data were analyzed using the first-order conditional estimation method with the
Interaction program.
For the population pharmacokinetic analysis, the plasma gentamicin concen-
trations were fitted to one-, two-, or three-compartment linear models using
subroutines from the NONMEM library (2). The concentration-time profile can
be described as (equation 1):
Yij fij i, xij  e1ij 2ij (1)
where yij is the jth observed concentration at time points xij for the ith subject. i
represents the fixed-effects parameter of the structural model to be estimated. fij
is the function for the prediction of the jth response for the ith subject. Finally,
εij denotes the jth measurement error for the ith subject. In other words, εij is the
difference of the observed concentration from the predicted concentration. It is
assumed to be independent and identically distributed with a normal distribution
around the mean zero and variance 2.
Between-subject variability and between-occasion variability. Between-subject
variability was modeled using an exponential variability model (equation 2):
i   ei (2)
where i is the value of the parameter for the ith subject;  is the typical value of
the parameter in the population; and finally, i is a random vector with normal
distribution, zero mean, and a variance-covariance matrix of between-subject
variability () to be estimated.
Model diagnostics. To assess model validity, statistical comparison of nested
models was undertaken in the NONMEM program on the basis of a 	2 test of the
difference in the objective function. A decrease in the objective function of 3.84
units (P  0.05) was considered significant. The goodness of fit was evaluated by
visual inspection of diagnostic scatter plots, including the observed and predicted
concentrations versus time, weighted residual versus time, and residual versus
predicted concentrations.
Bootstrap. A nonparametric bootstrap method (15) (n 
 1,000) was used to
study the uncertainty of all pharmacokinetic parameter estimates in the final
base model. From the bootstrap empirical posterior distribution, we have been
able to obtain the 95% confidence interval (2.5 to 97.5%) for the parameters, as
described previously (14).
Covariate screening. EDD-f was considered an essential covariate, and there-
fore, a base EDD-f model was established before other covariates were consid-
ered. The covariates analyzed were age, total body weight (normalized to 70 kg),
lean body weight (LBW; equation from Janmahasatian et al. [9]) normalized to
55 kg, the final plasma creatinine concentration prior to commencement of
EDD-f, and creatinine clearance estimated via the Cockroft-Gault equation
(using total body weight) normalized to 6 liters h1 and an adjusted aminogly-
coside dosing weight (3). Possible covariates were added into the model in a
stepwise fashion. Covariates were considered for inclusion in the model if they
were biologically plausible and there was improvement in the overall fit of the
base model, i.e., a decrease in the objective function (at least 3.84 units), a
decrease in the unexplained between-subject variability of the parameter, and a
decrease in residual unexplained variability.
Dosing simulations. Monte Carlo dose simulations of different weight-based
dosing regimens with differential delay between gentamicin dosing and com-
mencement of a 10-h treatment of EDD-f were undertaken using NONMEM.
The simulations used a 50-year-old male (total body weight, 70 kg; body mass
index, 23.6 kg/m2) with daily doses of 3 mg/kg of body weight, 4 mg/kg, 5 mg/kg,
or 7 mg/kg administered either at the beginning of EDD-f (no delay) or at 30
min, 1 h, 2 h, or 4 h before EDD-f commencement. Simulations of dosing every
48 h were also undertaken. Post-EDD-f dosing was not simulated, in line with
findings from a previous pharmacokinetic simulations study by Teigen et al.,
which demonstrated unacceptable gentamicin exposure when gentamicin was
administered posthemodialysis (18). Each Monte Carlo simulation generated
concentration-time profiles for 1,000 subjects per dosing regimen using the
parameters from the final covariate model. The abilities of the dosing regimens
to achieve predefined pharmacodynamic targets, a Cmax/MIC ratio of 10 or an
AUC0–24 of 70 to 120 mg  h/liter (4), were then compared.
RESULTS
Fourteen patients were enrolled, and 265 plasma samples
for gentamicin concentration determination were collected
throughout 28 dosing intervals. All patients were sampled dur-
ing the first dosing interval, with one patient being sampled
from one additional EDD-f treatment, three patients being
sampled during an additional two EDD-f treatments, and two
patients being sampled during an additional three EDD-f
treatments. Patient demographic and clinical details are de-
scribed in Table 1.
Population pharmacokinetic modeling was performed using
the concentration data from the plasma samples. The best base
model, obtained using the model-building criteria, consisted of
a two-compartment linear model with zero-order input and
exponential residual unknown variability. Other models could
not be supported, as they did not result in an improvement in
the objective function value or between-subject variability. Be-
tween-subject variability was included for all parameters ex-
cept non-EDD-f clearance (CLNEDD-f), which was considered
to be not appropriate for inclusion because standard dialysis
filters were used. A more mechanistic model contrasting dial-
ysis clearance with different dialysis membrane characteristics
was not explored, as all patients received a standard dialysis
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dose with the same dialyzers and membranes. A variance-
covariance matrix between clearance, central volume of distri-
bution, and peripheral volume of distribution was supported.
The model did not support between-occasion variability be-
tween any of the parameters. The final objective function for
the base model was 131.853.
The covariates that described gentamicin clearance were pa-
tient lean body weight (normalized to 55 kg) and the last plasma
creatinine concentration before commencement of EDD-f. The
addition of these parameters reduced the objective function by
10.032 and 45.023, respectively (a statistically significant
change is 3.84 units). The covariate that described the central
volume of distribution was total body weight normalized to 70
kg. The addition of this parameter reduced the objective func-
tion by 4.925. The objective function for the final covariate
model was 76.875. The final model for gentamicin clearance
was represented by equation 4:
TVCLNEDD-f 
 (1  LBW/55  FCR) (3)
TVCL 
 TVCLNEDD-f  TVCLEDD-f (4)
where TVCLNEDD-f is the typical value of non-EDD-f clear-
ance, LBW is lean body weight described by the equation from
Janmahasatian et al. (9) normalized to 55 kg, FCR is the
inverse of the final plasma creatinine concentration recorded
in micromoles/liter before commencement of EDD-f, and
TVCLNEDD-f is the typical value of clearance during EDD-f.
None of the other covariates statistically significantly improved
the model and therefore could not be included.
The values of the parameters for the final model are given
in Table 2. Table 2 presents the 95% confidence interval for
the parameters computed from all bootstrap runs. The pop-
ulation value for the clearance of gentamicin during EDD-f
(CLEDD-f) was 2.54 liters/h (half-life [t1/2], 13.8 h), whereas
it was 0.23 liter/h (t1/2 153.4 h) when EDD-f was not being
T
A
B
L
E
1.
D
em
ographic
and
clinicaldetails
of
enrolled
patients
a
Patient
no.
A
ge
(yr)
Sex
H
t
(cm
)
W
t
(kg)
A
dm
ission
diagnosis
V
entilator
duration
(days)
IC
U
L
O
S
(days)
A
PA
C
H
E
III
score
SO
F
A
score
1
73
M
166
78
Postlaparotom
y
28
38
98
12
2
57
M
180
127
M
ulitorgan
failure
11
19
94
14
3
49
M
187
182
Sepsis
8
9
124
14
4
52
M
166
111
C
ardiac
arrest
4
5
98
9
5
72
M
175
80
Sepsis
7
7
104
12
6
55
M
175
110
R
espiratory
failure
9
10
93
15
7
81
M
174
70
R
epair
of
ruptured
A
A
A
12
13
44
12
8
79
M
180
90
Subclavian-bifem
oral
graft
10
12
103
13
9
64
M
168
95
V
entriculoperitoneal
shunt
revision
8
13
135
11
10
87
M
166
79
L
aparotom
y
2
2
112
12
11
68
M
173
95
Sepsis
22
24
95
12
12
57
F
157
85
R
espiratory
failure
13
16
80
11
13
75
M
170
115
L
aparotom
y
9
20
96
7
14
62
M
185
80
N
eutropenic
sepsis
11
14
142
9
M
edian
(interquartile
range)
66.0
(57.0–74.5)
12
M
,1
F
173.5
(166.5–178.8)
92.5
(80.0–111.1)
9.5
(8.0–11.8)
13.0
(9.3–18.3)
98
(94–110)
12.0
(11.0–12.8)
a
G
roup
data
are
presented
as
m
edians
(interquartile
ranges).IC
U
L
O
S,intensive
care
unit
length
of
stay;A
PA
C
H
E
,A
cute
Physiology
and
C
hronic
H
ealth
E
valuation;SO
F
A
,SequentialO
rgan
F
ailure
A
ssessm
ent;
A
A
A
,abdom
inalaortic
aneurysm
;F
,fem
ale;M
,m
ale.
TABLE 2. Bootstrap parameter final estimates of the final
covariate model
Parametera Mean
95%
confidence
interval
Fixed effects
CLEDD-f (liters h
1) 2.59 1.91–4.16
CLNEDD-f (liters h
1) 0.24 0.17–0.32
Central vol of distribution (liters) 14.1 10.8–20.5
Peripheral vol of distribution
(liters)
32.8 27.25–47.4
Intercompartmental clearance
(liters h1)
2.76 1.48–6.7
Random effects, between-subject
variability BSV (% coefficient
of variation)
Clearance 39.9 7.8–52
Central vol of distribution 16.4 3.7–42.9
Intercompartmental clearance 20.5 57.7–137
Peripheral vol of distribution 110.5 9.1–56.4
Random error, residual unexplained
variability (% coefficient of
variation)
20.8 15.5–23.8
a CLEDD-f, clearance of gentamicin during EDD-f; CLNEDD-f, clearance of
gentamicin not due to EDD-f.
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used (CLNEDD-f). The population value for the volume of
distribution was 0.55 liter/kg.
Figure 1 displays the goodness-of-fit plots for the final
model. The weighted residual graph shows no apparent visual
or statistical bias for the prediction. Of the 265 samples in-
cluded in the analysis, 10 samples had a concentration greater
than 2 standard deviations outside that predicted by the model,
which we considered acceptable, given the level of sickness
severity and the likely pharmacokinetic heterogeneity of the
patient cohort. It was noted that the model underpredicted the
higher concentrations to a small extent. All subsequent dosing
simulations were then based on this model. All other visual
predictive checks were acceptable and confirmed the goodness
of fit of the model. The plots show that the final pharmacoki-
netic model adequately describes the measured gentamicin
concentrations when EDD-f is being used and when it is not
being used.
Dosing simulations. Multiple dosing schedules were evalu-
ated on the basis of the final covariate model and by assuming
an MIC of 1 mg/liter. The abilities of the different dosing
schedules to achieve predefined pharmacodynamic end points
(4) were evaluated on the basis of the final covariate model and
assuming an MIC of 1 mg/liter. None of the simulated doses
adequately achieved a target Cmin of 1.0 mg/liter, with the
best-performing dosage being a 3-mg/kg infusion finishing at
the time of EDD-f commencement, which achieved attainment
in 29% of the simulated patients. Achievement of the maximal
AUC0–24 (70 to 120 mg  h/liter) and Cmax (10 mg/liter) phar-
macodynamic targets for the simulated patients was by the
4-mg/kg or 5-mg/kg dose given either 30 min or 1 h before
commencement of EDD-f.
Simulations performed with dosing every 48 h achieved tar-
gets more successfully than dosing every 24 h. We compared a
96-h duration of therapy of 5 mg/kg every 24 h with 6 mg/kg
every 48 h. The median daily AUC0–24 for 5 mg/kg was 135.7
mg  h/liter (range, 85.8 to 188.3 mg  h/liter), which exceeded
the recommended range (70 to 120 mg  h/liter), whereas the
median AUC0–24 for dosing with 6 mg/kg every 48 h was more
favorable at 88.7 mg  h/liter (range, 48.4 to 122.0 mg  h/liter).
Both doses achieved a Cmax of 10 mg/liter in 99.9% of the
simulated patients. Figure 2 describes the comparative simu-
lated concentrations for the regimen of 5 mg/kg every 24 h and
the regimen of 6 mg/kg every 48 h. Figure 2 shows that the
schedule of 6 mg/kg every 48 h minimized the Cmin at 1.5
mg/liter, whereas dosing with 5 mg/kg every 24 h minimized the
Cmin at 2.2 mg/liter.
DISCUSSION
Knowledge of the significant clearance of gentamicin caused
by EDD-f can be used to procure dosing regimens that will
facilitate achievement of pharmacodynamic targets that are
FIG. 1. Goodness-of-fit plots for the final pharmacokinetic model. (a) Population predicted concentrations (mg/liter) versus weighted residuals;
(b) individual predicted concentrations versus observed concentrations. The black dotted line is the line of linear regression with an R2 value of
0.91, and the gray unbroken line is the line of x equal to y.
FIG. 2. Simulation data for gentamicin administered at 5 mg/kg every 24 h (with EDD-f commencing daily at 30 min postdosing) (a) and 6
mg/kg every 48 h (with daily EDD-f) (b). Simulations are presented as the expected concentrations for the 5th, 50th, and 95th percentiles of
simulated patients (n 
 1,000).
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associated with optimal antibiotic activity and a reduced po-
tential for toxicity. Administration of gentamicin before com-
mencement of EDD-f allows a high Cmax to be reached and
then utilizes EDD-f for rapid drug clearance to minimize the
Cmin and optimize the AUC0–24. Specifically, in the present
study we have shown that administering 6 mg/kg every 48 h (for
obese patients, we would recommend that this dose be based
on lean body weight) will ensure the maximal achievement
of AUC0–24 and Cmax targets (4) in patients with EDD-f for
infections caused by organisms with an MIC of 1 mg/liter.
It is likely that under this scenario an organism with an MIC
of 2 mg/liter cannot receive treatment that will achieve the
Cmax/MIC or AUC0–24/MIC pharmacodynamic targets or a
low Cmin.
Using a 24-h gentamicin dosing regimen with EDD-f does
not appear to enable drug exposures that would be desired to
minimize both nephro- and ototoxicity for critically ill patients
with AKI. The simulations in this paper show that none of the
simulated dosing regimens achieve a satisfactory Cmin (1.0
mg/liter). Although the 3-mg/kg regimens enable the highest
proportion of simulated patients to achieve a Cmin of 1.0
mg/liter, it is still achieved in only 29% of patients. This sug-
gests that the clearance of gentamicin by EDD-f is not suffi-
cient to reduce the likelihood of drug toxicity from once-daily
dosing. Extended-interval dosing, i.e., dosing every 48 h, may
be the solution to this problem, and the simulations performed
in the present study support use of dosing with 6 mg/kg every
48 h to maximize achievement of Cmax targets (assuming an
MIC of 1 mg/liter).
The correct prescription of gentamicin during EDD-f is
likely to be guided by the clinical scenario. While daily 7-mg/kg
dosing achieves the pharmacodynamic targets for maximal bac-
terial kill, it risks toxicity, whereas dosing gentamicin at 6
mg/kg every 48 h achieves appropriate Cmax and AUC0–24
targets with an improvement in Cmin targets as well. Smaller
doses do not achieve Cmax or AUC0–24 targets as proficiently as
higher doses and confer only a small decrease in the potential
for gentamicin toxicity (target Cmin). In the absence of achiev-
ing a target Cmin, minimizing the cumulative gentamicin expo-
sure is the most appropriate method to ensure prevention of
toxicity. Pursuant to this, we would advocate that short courses
(4 days) of gentamicin at 6 mg/kg every 48 h be used where
possible. The inherent pharmacokinetic variability observed in
critically ill patients mandates that therapeutic drug monitor-
ing still be undertaken to guide the timing of redosing after the
administration of the first dose. Achievement of AUC0–24 tar-
gets can then be facilitated by inputting two concentration-
time points (prelevel and postlevel) into freely available Bayes-
ian dosing software, such as TCI Works (available at www
.tciworks.info). Such an approach may enable more accurate
dosing as well as the use of longer courses of therapy with a
decreased likelihood of toxicity.
The volume of distribution of gentamicin in this cohort of
patients with AKI requiring EDD-f is largely similar to that
observed in previous studies of critically ill patients without
RRT requirements. The mean volume of distribution in our
study was 0.55 liter/kg, which compares favorably with amino-
glycoside data from Marik (0.41 liter/kg) (12), Dasta and Arm-
strong (0.36 liters/kg) (8), and Triginer et al. (0.43 liters/kg)
(19). The incrementally higher volume of distribution for this
cohort compared with the result from previous studies is likely
to be due to the high level of sickness severity of the patients
enrolled in the present study.
There are some limitations to the present study that we
would like to declare. First, due to the high volumes of dialy-
sate generated by EDD-f, it was not possible to determine the
concentration of gentamicin in the dialysate, and therefore, it
was assumed that clearance during EDD-f is due solely to
EDD-f. Second, our model was based on the homogeneous
EDD-f settings used in our intensive care unit, and therefore,
we are unable to extrapolate from these data the effect of
different blood flow or ultrafiltrate flow rates. Third, the sim-
ulations in the present study assume that EDD-f continues for
the planned 10-h duration of RRT treatment. In patients,
blood clotting on the filter frequently prevents this, and there-
fore, therapeutic drug monitoring remains an essential part of
redosing in such situations. Finally, the convenient sampling
used in the present study meant that this cohort had a high
proportion of obese patients (5 patients weighed greater than
100 kg) and 13 of the 14 patients were male. However, these
anomalies were explained pharmacokinetically in our model by
the inclusion of total body weight as a covariate of the central
volume of distribution. It is unlikely that clearance would be
significantly affected by gender or obesity because the predom-
inant clearance is caused by EDD-f.
Conclusions. Gentamicin remains an important antibiotic
for use in critical care units, but it is often withheld or inade-
quately dosed for fears of accumulation and toxicity in renal
failure. When it is used in patients with AKI, EDD-f results in
significant gentamicin clearance. In this paper, we have been
able to show that when it is dosed for 48 h, a dose of 6 mg/kg
gentamicin 30 min before the commencement of EDD-f results
in sufficient drug clearance to achieve the pharmacodynamic
targets associated with maximal bacterial killing. To achieve
the optimal therapeutic effect of gentamicin while minimizing
toxicity, inputting predose and postdose therapeutic drug mon-
itoring data into pharmacokinetic dosing software can be used
to determine personalized dosing regimens for critically ill
patients receiving EDD-f.
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